Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

Young Kwang Chae*, Muhammad Yousaf, Mary Kate Malecek, Benedito Carneiro, Sunandana Chandra, Jason Kaplan, Aparna Kalyan, Antonella Sassano, Leonidas C. Platanias, Francis Giles

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.

Original languageEnglish (US)
Pages (from-to)413-427
Number of pages15
JournalDiscovery medicine
Volume20
Issue number112
StatePublished - Jan 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Neoplasms
Therapeutics
Brain Stem Neoplasms
Combination Drug Therapy
Multiple Myeloma
Acute Myeloid Leukemia
Epidemiologic Studies
Hepatocellular Carcinoma
Colorectal Neoplasms
Appointments and Schedules
Cholesterol
Clinical Trials
Radiation
Pediatrics
Breast Neoplasms
Mortality
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chae, Y. K., Yousaf, M., Malecek, M. K., Carneiro, B., Chandra, S., Kaplan, J., ... Giles, F. (2015). Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? Discovery medicine, 20(112), 413-427.
Chae, Young Kwang ; Yousaf, Muhammad ; Malecek, Mary Kate ; Carneiro, Benedito ; Chandra, Sunandana ; Kaplan, Jason ; Kalyan, Aparna ; Sassano, Antonella ; Platanias, Leonidas C. ; Giles, Francis. / Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?. In: Discovery medicine. 2015 ; Vol. 20, No. 112. pp. 413-427.
@article{7f59059641a044fda19683abc9bf4ac6,
title = "Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?",
abstract = "Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.",
author = "Chae, {Young Kwang} and Muhammad Yousaf and Malecek, {Mary Kate} and Benedito Carneiro and Sunandana Chandra and Jason Kaplan and Aparna Kalyan and Antonella Sassano and Platanias, {Leonidas C.} and Francis Giles",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "20",
pages = "413--427",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "112",

}

Chae, YK, Yousaf, M, Malecek, MK, Carneiro, B, Chandra, S, Kaplan, J, Kalyan, A, Sassano, A, Platanias, LC & Giles, F 2015, 'Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?', Discovery medicine, vol. 20, no. 112, pp. 413-427.

Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? / Chae, Young Kwang; Yousaf, Muhammad; Malecek, Mary Kate; Carneiro, Benedito; Chandra, Sunandana; Kaplan, Jason; Kalyan, Aparna; Sassano, Antonella; Platanias, Leonidas C.; Giles, Francis.

In: Discovery medicine, Vol. 20, No. 112, 01.01.2015, p. 413-427.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

AU - Chae, Young Kwang

AU - Yousaf, Muhammad

AU - Malecek, Mary Kate

AU - Carneiro, Benedito

AU - Chandra, Sunandana

AU - Kaplan, Jason

AU - Kalyan, Aparna

AU - Sassano, Antonella

AU - Platanias, Leonidas C.

AU - Giles, Francis

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.

AB - Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.

UR - http://www.scopus.com/inward/record.url?scp=84954312641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954312641&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 413

EP - 427

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 112

ER -